Clinical Trial Update: Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the maximum tolerated dose of BAY1000394 given on a 3 days on / 4 days off schedule in subjects with advanced malignancies has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY1000394 (BAY1000394)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED